STRUCTURE-FUNCTION-RELATIONSHIPS IN HUMAN INTERLEUKIN-11 - IDENTIFICATION OF REGIONS INVOLVED IN ACTIVITY BY CHEMICAL MODIFICATION AND SITE-DIRECTED MUTAGENESIS

Chemical modification approaches combined with site-directed and deletion mutagenesis have been used to identify functionally critical regions/residues of recombinant human IL-11 (rhIL-11), Incubation of rhIL-11 with iodoacetic acid results in specific alkylation of a single methionine residue, Met(58), and a 25-fold reduction of in vitro biological activity on mouse plasmacytoma cells. A similar decrease in activity is observed when Met(58) is substituted with Ala, Leu, Gin, Glu, or Lys by site-directed mutagenesis. Treatment of rhIL-11 with succinic anhydride leads to modification of the aminoterminal amino group and partial labeling of 2 lysines, Lys(4l) and Lys(98), and to a 3-fold decrease in activity. The activity losses can be attributed to modification of the lysine residues, since the succinyl derivative of the amino terminus is fully active. In addition, carboxyl-terminal deletion mutagenesis studies have demonstrated that removal of the last 4 residues reduces rhIL-11 activity 25-fold, whereas removal of 8 or more amino acids results in an inactive molecule. Based on secondary structure predictions and the location of exon/intron boundaries in the IL-11 genomic structure, we propose a four-helix bundle topology as a structural model for rhIL-11. This model has been tested by limited proteolysis using three side chain-specific endoproteinases. A limited number of protease-sensitive cleavage sites are present in rhIL-11, and all but two are located in the postulated helix interconnecting loops or at helix termini, alpha-Helices, which in the proposed structure form a compact core of the molecule, are inaccessible to digestion under limiting conditions. According to the model, Met(58), Lys(41) and Lys(98) are located on the surface of the molecule, in agreement with their preferential accessibility to chemical modification. By analogy with human growth hormone, we postulate that Met(58) and the carboxyl terminus of rhIL-11 are involved in the primary receptor binding site (site I), whereas Lys(41) and Lys(98) may be a part of binding site II.